TxCell announces its financial calendar for 2015 30 January 2015 | By TxCell TxCell SA announces its financial calendar for 2015...
Minister announces £14m investment in stratified medicine 29 January 2015 | By Medical Research Council Minister for Life Sciences George Freeman announced a further £13.7 million investment in stratified medicine collaborations funded by the Medical Research Council (MRC)...
TxCell receives EUR 1 million milestone payment regarding Ovasave(R) collaboration agreement from Trizell 29 January 2015 | By TxCell Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease...
Tau-based vaccines could transform early Alzheimer’s Disease treatment, says GlobalData Analyst 28 January 2015 | By GlobalData While current treatments for Alzheimer’s Disease are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst with research and consulting firm GlobalData...
Genticel business update – fourth quarter 2014 28 January 2015 | By Genticel Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces its cash ans cash equivalents and liquid investments position and its highlights from the fourth quarter of 2014...
TxCell receives EUR 1.7 million from Bpifrance for Ovasave(R) clinical development in refractory Crohn’s disease 27 January 2015 | By TxCell TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces the receipt of EUR 1.7 million from Bpifrance...
Genticel to continue per protocol its Phase 2 clinical study with ProCervix after 2nd review by the DSMB 27 January 2015 | By Andrew Lloyd & Associates The Data and Safety Monitoring Board (DSMB) identified no safety concerns that would require making changes to the conduct of the study...
Syncona LLP and UCL Business PLC announce the formation of Autolus Limited, a cancer immunotherapy company 22 January 2015 | By UCL Syncona LLP and UCL Business PLC, the wholly-owned technology transfer company of University College London, announce the creation of Autolus Limited...
New Oncology and University Hospital Oslo announce genomic profiling collaboration 22 January 2015 | By B3C newswire New Oncology and the University Hospital Oslo announced today that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies...
Treeway announces License and Collaboration Agreement with uniQure to develop a Gene Therapy for Amyotrophic Lateral Sclerosis 16 January 2015 | By Treeway B.V. Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS...
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies 16 January 2015 | By Catalent Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
Isarna Therapeutics unveils new selective TGF-beta antagonist program targeting multiple indications in ophthalmology 13 January 2015 | By B3C newswire First-in-human study in advanced-stage Glaucoma to begin in 1H2015...
Biodesix raises additional series E financing 13 January 2015 | By Biodesix, Inc. Biodesix, Inc., announced that the company increased the size of its offering of series E preferred shares in a follow-on sale...
Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics 13 January 2015 | By Roche Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology 13 January 2015 | By Astrazeneca AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses...
